CYP19A1 and invasive breast carcinoma: Balanced matching without omitting any participant from the BrCa+/CIPN+ group was not possible for BrCa+/CIPN− when malignant BrCa was included or when SERM, aromatase inhibitors, and ovarian function suppressors were included as separate variables.